Recombinant Human EDA2R protein

The EDA2R (Ectodysplasin A2 Receptor) recombinant protein is a key component in studying signaling pathways related to ectodermal development and associated genetic disorders. EDA2R, also known as XEDAR (X-linked Ectodysplasin-A2 Receptor), belongs to the tumor necrosis factor receptor (TNFR) superfamily. It specifically binds to its ligand EDA-A2. a splice variant of ectodysplasin-A (EDA), to activate downstream NF-κB and JNK signaling cascades. This interaction plays a critical role in embryonic development, particularly in the formation of skin appendages, hair follicles, sweat glands, and teeth.

Mutations in the EDA/EDAR pathway are linked to X-linked hypohidrotic ectodermal dysplasia (XLHED), a genetic disorder characterized by abnormal development of ectodermal tissues. Recombinant EDA2R proteins are engineered to investigate molecular mechanisms underlying these pathologies and to develop therapeutic strategies. Produced through heterologous expression systems (e.g., mammalian cells or E. coli), the recombinant protein typically includes extracellular domains essential for ligand binding, enabling in vitro studies of receptor-ligand interactions.

Research applications include structural analysis of EDA2R-EDA-A2 complexes, screening for small-molecule modulators, and evaluating gene therapy approaches. Its recombinant form allows standardized experimental conditions for comparative studies across disease models. Recent advances in protein engineering have improved solubility and stability, facilitating high-resolution structural studies (e.g., X-ray crystallography) to map binding interfaces. This protein also serves as a tool for diagnosing EDA pathway-related disorders and validating CRISPR/Cas9-edited cellular models. Ongoing studies explore its potential in regenerative medicine for ectodermal tissue repair.